Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 9071 results

  1. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development Reference number: GID-TA11363 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tocilizumab for treating systemic sclerosis [ID1396]

    Awaiting development Reference number: GID-TA10346 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development

  5. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

    Technology appraisal guidance
    In development

  6. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lemborexan for treating insomnia [GID-TA12011]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing: draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 10 July 2026.

    NICE guideline
    In consultation

  10. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 17 July 2026.

    Technology appraisal guidance
    In consultation

  11. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 3 July 2026.

    In consultation

  12. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  13. Fenfluramine for treating seizures associated with Dravet syndrome in people under 2 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Secukinumab for treating moderate to severe hidradenitis suppurativa in people 12 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Mirikizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation